Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.92% | 74.61% | 32.67% | 13.21% | -758.15% |
| Total Depreciation and Amortization | -46.08% | -7.31% | -2.38% | 41.10% | 183.21% |
| Total Amortization of Deferred Charges | -- | -- | 0.00% | 0.00% | -- |
| Total Other Non-Cash Items | 754.40% | -160.23% | 40,839.02% | 350.08% | 68.27% |
| Change in Net Operating Assets | -519.09% | 660.64% | -124.68% | -140.88% | 120.72% |
| Cash from Operations | 63.45% | 52.73% | 30.85% | -55.39% | -19.98% |
| Capital Expenditure | 27.54% | -6.53% | -108.69% | 91.13% | 55.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.14% | -27.15% | -46.82% | 52.77% | -645.95% |
| Cash from Investing | 8.61% | -15.79% | -185.46% | 81.40% | 34.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.63% | -- | -100.00% | -92.23% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.63% | -115.27% | 956.23% | -183.56% | 144.21% |
| Foreign Exchange rate Adjustments | -7.40% | 268.83% | -99.43% | -45.79% | -171.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.20% | 42.13% | 182.25% | -78.37% | 1,465.86% |